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Objective: People with diabetes show great variability in weight gain and 
duration of obesity at the time of diagnosis. BMI trajectories and other 
cardiometabolic risk factors prior to type 2 diabetes were investigated.
Methods: A total of 6,223 participants from the Rotterdam Study cohort 
were included. BMI patterns before diagnosis of diabetes were identified 
through latent class trajectories.
Results: During a mean follow-up of 13.7 years, 565 participants devel-
oped type 2 diabetes. Three distinct trajectories of BMI were identified, 
including the “progressive overweight” group (n = 481, 85.1%), “pro-
gressive weight loss” group (n = 59, 10.4%), and “persistently high BMI” 
group (n = 25, 4.4%). The majority, the progressive overweight group, 
was characterized by a steady increase of BMI in the overweight range 
10 years before diabetes diagnosis. The progressive weight loss group 
had fluctuations of glucose and marked beta cell function loss. The per-
sistently high BMI group was characterized by a slight increase in insulin 
levels and sharp increase of insulin resistance accompanied by a rapid 
decrease of beta cell function.
Conclusions: Heterogeneity of BMI changes prior to type 2 diabetes was 
found in a middle-aged and elderly white population. Prevention strate-
gies should be tailored rather than focusing only on high-risk individuals.
Obesity (2020) 28, 1149-1156. 
Introduction
Observational studies have extensively shown BMI to be associated with risk for type 2 
diabetes (1). Notably, the number of people with diabetes is expected to increase dramati-
cally in the forthcoming years given the parallel increase in obesity rates worldwide (2,3). 
However, patients with diabetes show great variability in terms of weight, weight gain, 
and duration of obesity at the time of diagnosis (4-6). Consequently, understanding the 
complex pathophysiological mechanism regarding patterns of change in BMI might pro-
vide new insights into precision prevention strategies to confront the new epidemiological 
challenges of obesity and diabetes.
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Study Importance
What is already known?
►	Type 2 diabetes continues to be a public 
health threat worldwide, partly fueled by 
the increasing burden of obesity.
►	People with diabetes show great vari-
ability in terms of BMI, weight gain, 
and duration of obesity at the time of 
diagnosis.
What does this study add?
►	Using latent class trajectory analysis to 
model the patterns of BMI in the years 
before people developed diabetes, three 
different trajectories of BMI patterns 
were identified.
►	The majority of people (85.1%) were 
characterized by small weight gains 
within the overweight range before dia-
betes diagnosis, followed by people who 
lost weight during the study (10.4%). 
Unlike commonly expected, people 
with high BMI were the smallest group 
(4.4%). Our findings show that the ma-
jority of people might be missed from 
the screening efforts despite being at 
high risk. Prediction in these groups is 
difficult.
►	The results emphasize the complexity of 
diabetes pathophysiology in the popula-
tion and the need to stimulate debate for 
precision prevention strategies.
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Former population studies investigating BMI changes in association 
with chronic diseases such as cardiovascular disease (CVD) and dia-
betes have shown heterogeneous signatures of disease development 
across BMI trajectories. Previously, we identified three distinct pat-
terns of BMI prior to CVD development, and the majority of partici-
pants who developed the disease were characterized with a stable BMI 
over time, highlighting a heterogeneous nature of CVD not entirely 
attributed to BMI (7). Similarly, another study among 6,705 British 
participants showed three BMI patterns accompanied with distinctive 
cardiometabolic risk profiles, with the majority of individuals showing 
modest weight gain prior to diabetes diagnosis (8). This finding goes 
against the common assumption that people who experienced recent 
substantial weight gain are more likely to be diagnosed with diabetes. 
Before drawing firm conclusions on the process of diabetes develop-
ment, it is important to test whether similar trends are observed in other 
cohorts. Therefore, we aimed to identify and characterize BMI patterns 
in a European population of middle-aged and elderly individuals before 
diabetes development. Additionally, trajectories of cardiometabolic risk 
factors, including glycemic traits, lipids, blood pressure, and waist cir-
cumference, within each BMI pattern were further examined.
Methods
Study population
The study was performed among participants of the prospective pop-
ulation-based Rotterdam Study. In 1989, all residents aged 55 years 
or older in Ommoord, a suburb of Rotterdam, the Netherlands, were 
invited to participate in the study. Seventy-eight percent of the invitees 
agreed to participate (n = 7,983). There were no eligibility criteria to 
enter the Rotterdam Study cohorts except the minimum age and resi-
dential area based on postal codes. The participants of the Rotterdam 
Study have been followed up for more than 22 years for a variety of 
diseases, and clinical data have been collected across five subsequent 
phases every 3 to 4 years. A more detailed description of the Rotterdam 
Study can be found elsewhere (9). The Rotterdam Study has been ap-
proved by the medical ethics committee according to the Population 
Screening Act: Rotterdam Study, executed by the Ministry of Health, 
Welfare and Sports of the Netherlands. All participants in the present 
analysis provided written informed consent to participate and to obtain 
information from their treating physicians.
For this study, we used visits of the first cohort. From 7,983 participants 
at baseline, we excluded 225 without informed consent, 916 with preva-
lent diabetes, 743 without BMI measurement throughout phases 1 to 5, 
and 1 with missing information of diabetes follow-up. The final sample 
included 6,098 individuals (Figure 1).
Assessment of BMI and other cardiometabolic 
risk factors
Height and weight were measured with the participants standing with-
out shoes or heavy outer garments. BMI was calculated as weight 
divided by height squared (kilograms per meter squared). Waist cir-
cumference was measured at the level midway between the lower 
rib margin and the iliac crest with participants in standing position 
without heavy outer garments and with emptied pockets, breath-
ing out gently. Information on cardiometabolic risk factors was ob-
tained through home interviews or measured at the study center, as 
Figure 1 Flow diagram of the study participants for each phase.
Rotterdam Study, Cohort 1
n=7983 Excluded:
No informed consent 
(n=225)
Prevalent diabetes (n=916)
Missing information on 
BMI measures and diabetes 
follow-up data at any of the 
Phases 1-5 (n=744)
Phase 1 (RS I-1)
n=6098
Phase 2 (RS I-2)
n=4761
Phase 3 (RS I-3)
n=3686
Phase 4 (RS I-4)
n=2613
Phase 5 (RS I-5)
n=1488
Measures included in the 
study:
Body mass index (Phase 
1,2,3,4,5)
Waist circumference (Phase 
1,3,4,5)
Systolic and diastolic blood 
pressure (Phase 1,3,4,5)
Total and high density  
lipoprotein (HDL) 
cholesterol, triglycerides 
(Phase 3,4,5 measured as 
fasting)
Glucose, Insulin (Phase 
3,4,5 measured as fasting)
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previously described (10,11). Height and weight were measured in all 
five phases, whereas systolic and diastolic blood pressure and waist 
circumference were measured in phases 1, 3, 4, and 5, and fasting total 
cholesterol, high-density lipoprotein (HDL), cholesterol, and fasting 
plasma glucose were measured in phases 3, 4, and 5 (Figure 1). Serum 
total cholesterol, HDL cholesterol, and glucose were measured using 
standard laboratory techniques. Blood pressure was measured at the 
right brachial artery with a random-zero sphygmomanometer with the 
participant in sitting position, and the mean of two consecutive mea-
surements was used. Smoking status was classified as current smoking 
or others (former and never) in all phases. We assessed medication use 
for hypertension, hyperlipidemia, and diabetes through interview data.
Clinical outcome
The participants were followed from the date of baseline center visit 
onward. At baseline and during follow-up, cases of type 2 diabetes 
were ascertained by use of general practitioners’ records (including 
laboratory glucose measurements), hospital discharge letters, and 
serum glucose measurements from Rotterdam Study visits, which 
take place roughly every 4 years. According to the World Health 
Organization guidelines, type 2 diabetes was defined as a fasting 
blood glucose > 7.0 mmol/L or the use of blood glucose–lowering 
medication (12). Information regarding the use of blood glucose–
lowering medication was derived from both structured home inter-
views and linkage to pharmacy records. At baseline, more than 95% 
of the Rotterdam Study population was covered by the pharmacies in 
the study area. All potential events of prediabetes and type 2 diabe-
tes were independently adjudicated by two study physicians. In case 
of disagreement, consensus was sought with a specialist. Follow-up 
data were completed until January 1, 2012 (13).
Statistical analysis
We used χ2 tests for categorical variables and t tests for continuous data 
when comparing the general characteristics between groups. Latent class 
trajectory analysis was performed to identify groups of participants with 
similar trajectories of BMI change during follow-up until the occurrence 
of diabetes, as previously described (7,14). Regarding BMI trajectories, 
the groups are different from each other but not different within the 
class. This method does not allow for within-class variation (as opposed 
to, for example, growth mixture modeling). Next, within each identified 
BMI group, the trajectories of change in other cardiometabolic risk fac-
tors during the time before diabetes diagnosis were developed (7).
The analysis was conducted by taking into account information from 
the population retrospectively from the date of diabetes diagnosis. The 
model used for latent class trajectories is a linear mixed-effects model 
with BMI as the dependent variable and time before diagnosis (time 
0), age, sex, and phase of study as independent variables. The variable 
“time before diabetes diagnosis” describes the shape of the trajectories 
of BMI and it was entered in the model as a covariate in a cubic spec-
ification. To assign the number of classes in the analysis, the Bayesian 
information criterion was used. The latent class trajectory model cal-
culates a posterior probability of membership in each latent class for 
each participant, who is later assigned to the class for which his/her 
posterior probability is the highest. In order to ensure statistical and 
clinical meaningfulness, the following two conditions were imposed in 
the formation of latent classes: (1) they should contain at least 5% of 
participants, and (2) the mean posterior probability of each class should 
be higher than 75%.
Because the trajectories of change in BMI could differ between individ-
uals who die during follow-up and among individuals who do not die 
or develop diabetes during follow-up (15), we divided the rest of the 
population into the following two subgroups: (1) diabetes-free and alive 
until end of follow-up and (2) nondiabetes mortality. For each identified 
BMI group (among individuals diagnosed with diabetes) and the two 
other groups (diabetes-free and nondiabetes mortality), we examined 
the trajectories of other cardiometabolic risk factors, including waist 
circumference, systolic and diastolic blood pressure, fasting total choles-
terol, low-density lipoprotein (LDL) cholesterol, HDL cholesterol, fast-
ing plasma glucose, and fasting plasma insulin. The homeostatic model 
assessment was used to estimate insulin resistance (HOMA-IR) and beta 
cell function (HOMA-%B) (16). The absolute 8-year risk of developing 
type 2 diabetes was calculated in all participants using the Framingham 
diabetes risk score (17), and the Framingham CVD risk score was used to 
estimate the 10-year absolute risk of developing CVD (18). In our study, 
cardiovascular disease is composed of coronary heart disease (including 
fatal and nonfatal myocardial infarction and other coronary heart disease 
mortality) and stroke (fatal and nonfatal stroke), as previously described 
(10,19,20).
Because the aggregated effect of combined risk factors on diabe-
tes might differ from each risk factor alone, we examined the tra-
jectories of 8-year diabetes risk and 10-year diabetes risk in each 
BMI group. The predicted 10-year CVD risk was calculated using 
the American College of Cardiology/American Heart Association 
Pooled Cohort Equation coefficients, which include age, sex, total 
cholesterol, HDL cholesterol, systolic blood pressure, blood pres-
sure–lowering medication use, diabetes status, and smoking status 
in the prediction model (15). These trajectories of cardiometabolic 
risk factors were estimated using linear mixed-effects models con-
trolling for follow-up time, age, sex, and study phase. Analyses of 
lipids were further adjusted for lipid-lowering treatment, analyses of 
blood pressure were further adjusted for antihypertensive treatment, 
and analyses of glucose were additionally adjusted for diabetes treat-
ment. Quadratic and cubic terms for follow-up time were included 
in the BMI groups (latent classes) when significant (P < 0.05). For 
individuals not developing diabetes during follow-up (diabetes-free 
and nondiabetes mortality groups), year 0 is merely a time point in a 
normal life course, and we therefore fitted the trajectories by using 
linear models. Pairwise differences in growth curves between BMI 
groups were tested using F  tests for each cardiometabolic risk fac-
tor. A χ2 test (for categorical variables) was used to compare par-
ticipant characteristics between the groups. To account for multiple 
testing because of comparing three pairs of BMI groups, we used 
a Bonferroni-adjusted significance level of 0.05/3 = 0.0167 for the 
F tests for each cardiometabolic risk factor. All other statistical tests 
used a significance level of 0.05, and all statistical tests were two 
sided. Analyses were conducted using R statistical software, version 
3.0.1 (R Foundation for Statistical Computing, Vienna, Austria), with 
the package ‘‘lcmm’’ (10).
Results
Baseline characteristics of the study population are presented 
in Table 1. Overall, 6,223 participants with a mean age of 
68.8 years, mostly women (n = 3,681, 59.2%) and overweight (mean 
BMI = 26.24), were included in the study. The mean (SD) follow-up 
time was 13.7 (6.5) years, during which 565 participants devel-
oped diabetes. Among individuals who did not develop diabetes, 
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1,891 (30%) remained alive until the end of follow-up and 3,767 
(60.5%) died from nondiabetes causes. The baseline characteristics 
of these subgroups are presented in Supporting Information Table S1. 
Table 2 shows characteristics of the participants at the time of diabe-
tes diagnosis for all trajectories’ groups or at the last examination for 
participants without diabetes.
Patterns of BMI change over time
Among 565 participants who developed diabetes, we identified three 
distinct trajectories of change in BMI levels (Figure 2). The first group 
(n = 481, 85.1%) representing the majority of individuals who devel-
oped diabetes, entered the study with a mean BMI of 28.0 and expe-
rienced an increase in BMI within the overweight range. This group 
was named “progressive overweight.” Thereafter, the second group 
(n = 59, 10.4%), who initially started with an average BMI of 26.6, 
continued to experience a decrease in BMI during the entire follow-up. 
We named this group ‘‘progressive weight loss.’’ The third group com-
prised 25 (4.4%) individuals who entered the study with an average 
BMI of 35.4 and maintained their obesity status with fluctuating BMI 
values within the obesity range during the entire follow-up until diag-
nosis of diabetes. Therefore, we named this group “persistently high 
BMI.”
Among 1,891 participants who did not develop diabetes and who were 
alive until the end of follow-up, the “diabetes-free” group, the average 
BMI remained relatively stable (ranging from 25.9 to 27.3 during fol-
low-up). Among 3,767 who died of other causes during follow-up, the 
“nondiabetes mortality” group, the average BMI at the start of the fol-
low-up was in the overweight range (average BMI = 26.4) and it reached 
the normal range just before the end of follow-up. The analysis was 
performed in the total population, but in order to plot the trajectories 
of change in BMI and other cardiometabolic risk factors, we assumed 
a hypothetical individual to be a male of 65 years of age. Similar tra-
jectories for a hypothetical woman of 65 years of age are shown in 
Supporting Information Figures S1-S4.
Trajectories of waist circumference
Trajectories of waist circumferences differed significantly between 
the three groups (P < 0.001 for all pairwise comparisons) (Figure 2). 
The trajectories for the progressive overweight, persistently high BMI, 
and progressive weight loss groups broadly resembled the trajectories 
of BMI in these groups. The mean waist circumference in the diabe-
tes-free and nondiabetes mortality groups decreased slightly during 
follow-up.
TABLE 1 Characteristics of study participants at first clinical 
visit
N 6,223
Age (y) 68.82 (8.85)
Gender (% women) 3,681 (59.2)
Time before diagnosis/last visit (y) 13.75 (6.55)
BMI (kg/m2) 26.24 (3.70)
Waist circumference (cm) 90.15 (11.10)
Systolic blood pressure (mm Hg) 138.54 (22.00)
Diastolic blood pressure (mm Hg) 73.82 (11.44)
Total cholesterol (mmol/L) 5.83 (0.99)
LDL cholesterol (mmol/L) 3.76 (0.91)
Triglycerides (mmol/L) 1.49 (0.71)
HDL cholesterol (mmol/L) 1.41 (0.40)
Glucose (mmol/L) 5.68 (0.93)
Insulin (pmol/L) 78.68 (61.44)
HOMA-IR (units) 123.54 (119.42)
HOMA-%B (units) 1,642.76 (1,111.59)
Antihypertensive treatment (%) 894 (17.0)
Lipid-lowering medication (%) 474 (13.6)
Current smoker (%) 1,393 (23.1)
Data are n (%) or mean (SD).
Fasting measurements of lipids and glycemic indices were available at third, fourth, 
and fifth visits of original Rotterdam Study cohort.
HDL, high-density lipoprotein; HOMA-%B, homeostatic model assessment-beta cell 
function; HOMA-IR, homeostatic model assessment-insulin resistance; LDL, low-
density lipoprotein.
TABLE 2 Characteristics of study participants at diagnosis for three groups with diabetes or at last visit for groups without 
diabetes
 
Individuals developing diabetes during follow-up 
(n = 565)
Individuals free of diabetes during 
follow-up (n = 5,658)
Weight loss,
n = 59
Progressive 
weight gainers,
n = 481
Persistently 
high BMI,
n = 25
Diabetes-free,
n = 1,891
Nondiabetes mortality,
n = 3,767
Age at diagnosis/last contact (y) 67.2 (7.2) 66.4 (7.0) 64.5 (5.2) 62.2 (5.0) 72.4 (8.5)
Women (%) 30 (50.8) 282 (58.6) 20 (80.0) 1230 (65.0) 2,119 (56.3)
BMI (kg/m2) 24.9 (2.9) 28.9 (3.3) 39.0 (3.8) 27.3 (4.1) 26.2 (3.9)
Waist circumference (cm) 90.5 (9.9) 98.3 (10.3) 117.7 (20.8) 91.3 (11.9) 92.6 (11.5)
Antihypertensive treatment (%) 23 (39.7) 200 (42.8) 20 (83.3) 883 (47.6) 1021 (29.3)
Lipid-lowering medication (%) 11 (22.9) 62 (23.9) 5 (29.4) 420 (26.6) 255 (16.2)
Current smoker (%) 22 (43.1) 113 (32.7) 6 (30.0) 325 (18.4) 866 (32.2)
Data are n (%) or mean (SD).
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Trajectories of glycemic indexes (glucose, insulin, 
and HOMA-IR measurements)
Trajectories between fasting glucose levels differed between progres-
sive overweight and persistently high BMI when compared with the 
progressive weight loss group (Figure 3). The mean glucose levels 
of the latter were fluctuating for the whole follow-up time. For the 
progressive overweight and persistently high BMI groups, we observed 
an increase in mean levels of fasting glucose from 4.9 mmol/L to 
9.4 mmol/L during follow-up.
All three groups showed significantly different trajectories for fasting 
insulin. The progressive overweight group experienced an increase in 
Figure 2 Trajectories of BMI and waist circumference during 22 years of follow-up until diagnosis of type 2 diabetes, 
death, or censoring from the study. The figures represent a hypothetical man of 65 years old. Light blue, “progressive 
overweight” (including 85.1% of diabetes patients); red, “persistently high BMI” (4.4% of diabetes patients); dark 
blue, “progressive weight loss” (10.4% of diabetes patients); gray, “diabetes-free"; black, “nondiabetes mortality.” 
[Color figure can be viewed at wileyonlinelibrary.com]
Figure 3  Trajectories of fasting plasma glucose, insulin, and homeostatic model assessment-insulin resistance 
(HOMA-IR) and homeostatic model assessment-beta cell function (HOMA-%B) during 14 years of follow-up until 
diagnosis of type 2 diabetes, death, or censoring from the study. The figures represent a hypothetical man of 65 
years old. Light blue, “progressive overweight” (including 85.1% of diabetes patients); red, “persistently high BMI” 
(4.4% of diabetes patients); dark blue, “progressive weight loss” (10.4% of diabetes patients); gray, “diabetes-free”; 
black, “non-diabetes mortality.” [Color figure can be viewed at wileyonlinelibrary.com]
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mean insulin levels (from 67 mmol/L to 109 mmol/L) during follow-up. 
A slight increase was observed for the persistently high BMI group, 
which exhibited high insulin levels throughout the period, whereas 
modest decreases in insulin levels were observed for the progressive 
weight loss group.
Trajectories of HOMA-IR differed between all three groups (P < 0.01 
for all pairwise comparisons), demonstrating an incremental trend. The 
biggest increase was observed for the  progressive overweight group 
(from 67 mmol/L to 258 mmol/L), followed by the persistently high 
BMI group, which was characterized by the highest average HOMA-IR, 
and lastly, the  progressive weight loss group. On the contrary, 
a decreasing trend was observed for HOMA-%B for all the trajectories. 
The persistently high BMI group exhibited the highest average levels 
of HOMA-%B accompanied by a steep decrease during follow-up. The 
progressive overweight group showed a stable trend with an average 
of 1,500 mmol/L, whereas the progressive weight loss group experi-
enced lowered HOMA-%B levels from 1,200 mmol/L to 700 mmol/L 
(Figure 3).
Trajectories of lipid profile and blood pressure
We found no differences in fasting total cholesterol levels, HDL, LDL, 
and triglycerides between the three groups of individuals who devel-
oped diabetes during follow-up (Figure 4). For total cholesterol, we ev-
idenced a marked increase in the persistently high BMI group starting 
from 4.5 mmol/L. The other two groups kept a lowering trend through-
out the study, with all groups having an average total cholesterol level 
within the reference range (< 5.5 mmol/L). On the contrary, decreasing 
levels of HDL were observed for both the progressive overweight and 
Figure 4 Trajectories of total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) 
cholesterol, triglycerides, systolic blood pressure, and diastolic blood pressure. The figures represent a hypothetical 
man of 65 years old. Light blue, “progressive overweight” (including 85.1% of diabetes patients); red, “persistently 
high BMI” (4.4% of diabetes patients); dark blue, “progressive weight loss” (10.4% of diabetes patients); gray, 
“diabetes-free”; black, “nondiabetes mortality.” [Color figure can be viewed at wileyonlinelibrary.com]
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persistently high BMI groups, while the average levels of the progres-
sive weight loss group remained stable throughout the follow-up. For 
LDL and triglyceride levels, the persistently high BMI group exhib-
ited an increasing trend before the diabetes event. The average levels 
of LDL cholesterol demonstrated a modest decrease in the progressive 
overweight and progressive weight loss groups; meanwhile, the trend 
was reversed in both groups for triglyceride levels during follow-up.
Trajectories of systolic and diastolic blood pressure differed signifi-
cantly between all BMI groups. Both the progressive overweight and 
persistently high BMI groups showed an increasing trend before diag-
nosis of diabetes in both systolic and diastolic blood pressure levels, 
whereas the progressive weight loss group was relatively stable during 
follow- up (Figure 4).
Trajectories of estimated 8-year type 2 diabetes 
risk
Framingham 8-year diabetes risk followed nearly the same stable trend 
for the  progressive weight loss, diabetes-free, and nondiabetes mor-
tality groups (Supporting Information Figure S4A). The persistently 
high BMI group demonstrated an increase of 8-year diabetes risk from 
6% to 19% before diabetes diagnosis. A decreasing trend was shown for 
the progressive overweight group with a difference of nearly 4% to 5%.
Discussion
We examined BMI trajectories in a middle-aged and elderly popula-
tion-based study with  more than 20 years of follow-up  using latent 
class trajectory analysis and identified the following three distinct 
groups of BMI changes: a “progressive overweight” group, a “per-
sistently high BMI” group, and a group with “progressive weight loss.” 
Within the BMI groups that developed diabetes, trajectories of obesity, 
visceral fat as measured with waist circumference, glucose, insulin, 
HOMA-IR, and HOMA-%B showed distinct patterns throughout the 
follow-up of the study. This study shed further insights into the timing 
and the extent of pathophysiological changes before diabetes diagno-
sis in a middle-aged and elderly European population, highlighting the 
heterogeneous nature of diabetes diagnosis depending on the level of 
obesity.
The majority of individuals in our study diagnosed with diabe-
tes were progressively gaining weight within the overweight range. 
Development of diabetes was not preceded by a recent weight gain, as 
commonly believed, but rather by a continuous weight gain over the 
years. Similarly, in the study from Vistisen et al. (8), most of the indi-
viduals were found to have overweight when they entered the study 
and changed very little during follow-up until diabetes diagnosis. While 
there was relatively stable HOMA beta cell function, they exhibited 
progressively increasing trends of insulin levels and HOMA-IR starting 
from the beginning of the follow-up, whereas glucose levels increased 
substantially approximately 5 years before the diagnosis. The per-
sistently high BMI group showed prominent trajectories of glucose 
metabolism parameters as compared with the progressive overweight 
group. These results are in line with a previous study investigating BMI 
trajectories in relation to glucose and insulin metabolism; individuals 
with similar persistently high BMI were characterized by a high level 
of beta cell function (an adaptive response of the pancreas to obesity), 
which decreased over time. Similar trends were followed by high 
plasma insulin levels and insulin resistance (21).
As expected, Framingham 8-year diabetes risk was predicting well for 
the persistently high BMI group. In the progressive overweight group, 
we observed a decreasing trend of the predicted risk for diabetes 
throughout the period of follow-up, whereas the progressive weight 
loss group did not change substantially. These results might suggest 
that the diagnosis of diabetes might be biased toward enhanced screen-
ing efforts reserved to individuals with obesity rather than overweight. 
Similar findings were reported in an investigation of obesity trajec-
tories prior to diabetes development in a UK study (8). The “stable 
overweight” group was less often diagnosed with diabetes by general 
practitioners than the “persistently high BMI” group. This indicates an 
inclination of physicians to more effectively screen individuals with 
obesity in comparison to individuals with overweight.
We found that 10.4% of participants (second largest group) experi-
enced progressive weight loss before diagnosis of diabetes, a pattern 
not observed in the UK investigation (8). In an Austrian study of older 
adults, three trajectories of BMI before diabetes diagnosis were dis-
covered, two of which were characterized by a plateau or increase fol-
lowed by a decrease of BMI (22). These groups had increased overall 
and diabetes mortality. Among the elderly, the relation between body 
weight, body composition, and health behaviors is different from 
younger adults (23,24). Weight loss has often been associated with a 
high risk for mortality (15,22,25,26), while its association with CVD 
still remains inconclusive (26,27). In this group, waist circumference 
trajectories followed the same decreasing trend as BMI, while fluctu-
ations of fasting glucose levels with a sharp increase 5 years before 
diabetes diagnosis were observed. However, these changes did not 
correspond to an increase of insulin levels, while HOMA-%B levels 
were the lowest among the three groups, decreasing constantly. Despite 
the weight loss progression prior to diabetes diagnosis, the inability to 
respond adequately to high glucose levels, together with the impaired 
beta  cell compensation from the pancreas, appears to be involved in 
the disease development regardless of obesity levels. Individuals in this 
group might benefit from strategies focusing on prevention of further 
loss of beta cell function rather than tackling peripheral insulin sensi-
tivity. This concept is supported by previous work (28,29) and by our 
recent observation in a family study (30).
Despite the differences in BMI trajectories, most of the other car-
diometabolic risk factors, including blood pressure and lipid profile, 
developed without substantial changes in the three groups. Moreover, 
we were able to assess medication data for all BMI subgroups, and 
we found that antihypertensive medication and lipid-lowering drugs 
were more frequently used among the persistently high BMI individ-
uals followed by progressive overweight and progressive weight loss 
groups. This data showed that, most likely, individuals with over-
weight and those losing weight over time are less likely to receive 
medication. Notably, the progressive overweight group and progres-
sive weight loss group constituted more than 95% of the middle-aged 
and elderly population developing diabetes events. Therefore, ade-
quate treatment for these categories of patients could have a sub-
stantial impact on decreasing the overall burden of diabetes and 
associated comorbidities in the total population.
In recent years, many statistical methods have been developed to 
explore trajectories of BMI, including population-level growth 
curves, hierarchical clustering, mixed-effects models, etc. (21-22,31). 
Although they might contribute to our understanding of pathophysio-
logical mechanisms, they offer a simplified scenario of the complex-
ity and heterogeneity of disease. In our quest for precision medicine, 
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identification of homogeneous groups in terms of risk patterns may 
facilitate stratification for targeted interventions. In this regard, latent 
class trajectory analysis allows for the identification of classes of 
people who are very similar toward the development of a particular 
factor over time, but at the same time, they are different when com-
pared with other groups.
Strengths of our study include the prospective design with availabil-
ity of repeated measurements for BMI and other cardiometabolic risk 
factors, including medication use data, over a long follow-up time, 
which altogether allowed performing latent class trajectory analysis. 
Previous literature has used BMI in predefined categories, which might 
introduce some misclassification bias, whereas our analysis allows full 
exploration of heterogeneous patterns of BMI changes that might influ-
ence diabetes risk. Nevertheless, one of the drawbacks of this method is 
the assigned not-balanced sample size pertaining to the groups, which 
makes comparisons of the result difficult in the light of statistical 
power. In addition, generalizability of the study may be limited because 
of the specific population analyzed. The majority of individuals were 
middle-aged and elderly, with a mean age of 68.8 years old.
In conclusion, we identified three distinct patterns of BMI changes prior 
to diagnosis of type 2 diabetes. These population patterns contribute to 
our understanding of the complex etiology and pathophysiology of type 
2 diabetes and the challenges that arise when implementing weight-loss–
intervention programs for diabetes management. In the realm of precision 
medicine, we were able to identify groups with similar BMI trajectories 
by employing latent class trajectory analysis that might facilitate stratifi-
cation for targeted interventions in the future. It has always been expected 
that individuals who are more prone to develop diabetes are those with 
obesity or those who gained substantial weight recently. However, we 
found the majority of individuals were characterized by small weight gain 
(within the overweight range) during follow-up before diabetes diagno-
sis. In line with previous research, we showed that many individuals with 
overweight or normal weight might be missed from screening efforts 
(as measured, for example, with Framingham risk score), although they 
are at high risk. Therefore, prediction in these groups is difficult. Future 
studies should establish how to better target these subgroups and develop 
precision management strategies to prevent diabetes.O
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